Perhaps the most striking growth ai research in recent years has been the new techniques in molecular biolog] of genetic disease (Weatherall 198 these techniques are now being use wide range of inherited disorders, th( ible and thus the most extensively stu affecting haemoglobin production. structural haemoglobin abnormali sickle-cell disease (Bunn et al. 19 thalassaemiasin which the rate of one or other globin chain is reduce & Clegg 1981). It has been estima 200 000 children are born each year form of one of these conditions. N children will die in infancy, althoul care with blood transfusion, iron ( antibiotics is now becoming more wi( offering some a reasonable expec but at considerable expense. The improved understanding of the m( for these disorders will ultimately le; ful forms of management, but the s of these conditions and the numbe molecular lesions that have so far b make this a daunting task.
A significant advance in the mz some of the haemoglobin disorders development of methods of antenm which permit early detection an( abortion of affected fetuses (Alter Is now be done by chorionic biopsy as weeks, but it requires a high degre skill and is unlikely to be accepte( Neither antenatal diagnosis nor gei ling is a satisfactory answer to the genetic disease, and a definitive apl corrects or compensates for the d is required. Possibly the most wid approach to management is that of' (Anderson 1984) , in which normal some way inserted into affected cells of the technology for gene manipu] has been developed, this approach reached a stage where clinical trials taken. Obvious problems will inclu( the gene to work in the correct cells that the manipulations involved do individual's genetic apparatus in un possibly harmful ways. et al. 1977) . This switch from fetal to adult 2). Although haemoglobin involves a precisely timed change -d to tackle a from expression of y genes to the adjacent ,B genes; e most accessy chain (and thus HbF) production continues at died are those low levels during adult life in a small proportion These include of cells, and may increase slightly at times of ities such as erythroid stress, such as after bleeding and during )77), and the pregnancy or recovery from drug-induced marrow production of aplasia (Wood & Weatherall 1983) . Interestingly, d (Weatherall HbF interacts with sickle Hb (HbS) in vitro to Lted that over prevent sickling, and it has been recognized for with a severe some time that a milder form of sickle-cell disease Iany of these occurs in patients with sickle-cell disease who have gh supportive simultaneously inherited an ability to produce chelation and increased amounts of HbF during adult life dely available, (Perrine et al. 1978) . Similarly, interactions tation of life between hereditary persistence of fetal haemohope is that globin and determinants for severe forms of olecular basis IJ-thalassaemia seem to lead to a milder form of ad to success-thalassaemia, presumably because continued pro-,heer diversity duction of y chains offsets the relative excess of a r of different chains which are thought to be responsible for keen identified many of the clinical features of the disease (Weatherall & Clegg 1981) . If one could in some anagement of way prevent the switch from fetal-to-adult haemohas been the globin production at birth, or reactivate y chain atal diagnosis expression at a later stage, it might then be possd subsequent ible to ameliorate the clinical effects of these fi gene 984). This can disorders. early as 8-12
Not surprisingly, there has been considerable e of technical interest in the cellular and molecular events d universally. underlying the control of globin gene expression netic counsel- (Stamatoyannopoulos & Nienhuis 1979 , problems of 1983 , not only because of the therapeutic possibilproach which ities outlined above, but also because of the wider lefective gene understanding that would follow about general lely discussed mechanisms of gene regulation. An important 'gene therapy' question, which has not yet been completely genes are in resolved, is how is the timing of the switch Whilst much regulated? For instance, are the haemopoietic cells lation in vitro programmed in some way to switch at a specific has not yet time-and if so, how-or do they only switch can be under-in response to changes in or signals from their de persuading environment? It is generally agreed that the most and ensuring direct approach to this question is to transplant not alter the fetal haemopoietic cells into an adult environment iintended and and to study the pattern of haemoglobin synthesis by the transplanted cells (Zanjani et al. 1979 , Bunch et al. 1981 . Transplantation of fetal haemopoietic cells has been attempted in the treatment of congenital immune deficiencies and in some patients with leukaemia, but sustained haemopoietic engraftment has rarely been obtained (Lucarelli et al. 1980) . In one reported case (Delfini et al. 1983) , successful engraftment was associated with production of significant amounts of fetal haemoglobinpresumably by donor cellssuggesting little if any environmental effect. More substantial evidence comes from a large series of experimental transplants in sheep (Bunch et al. 1981 . Sheep are one of the few animal species to have, like man, a separate fetal haemoglobin (Wood et al. 1976) , and have the additional advantage of a common haemoglobin polymorphism which allows one to determine unambiguously whether adult haemoglobin produced after transplantation is of donor or recipient origin. Normal gestation in sheep is 145 days, and haemoglobin switching commences at 110-120 days. When cells of around 100 days gestation were transplanted into adult animals, predominantly adult haemoglobin of donor origin was produced, suggesting an immediate environmental effect (Zanjani et al. 1979 ). However, much younger cells (70 days gestation onwards) produced predominantly fetal haemoglobin, but later switched to adult haemoglobin production at a time related to the gestational age of the cells, as would be expected if they were obeying an internal program (Wood & Bunch 1983 . Interestingly, the overall timing of the switch in the transplanted cells was about 20 days earlier than expected, suggesting that environmental factors could still play a part. For example, an internal program could simply regulate the expression, at around 100 days, of a receptor for an environmental factor which is actually responsible for initiating the switch, but which does not appear until 120 days. An alternative explanation for the observed acceleration of the switch suggests a mechanism by which an internal program could operate: to prevent graft rejection, recipient lambs were heavily irradiated, and the limited numbers of stem cells transplanted would thus be under considerable pressure to increase their numbers by cell division in order to repopulate the empty marrow. Could switching therefore be controlled simply by a cellular 'time clock' which counts the number of cell divisions? It may be possible to confirm this by experiments which artificially increase the rate of cell division in fetal stem cells, and it is of interest that this sort of mechanism has been demonstrated in other developmental systems (Satoh 1984) .
The transplantation approach is technically difficult , and has been open to some criticism (see discussion following Wood & Bunch 1983) . A particular worry is that one may be transplanting a fetal microenvironment along with the haemopoietic stem cells, which could continue to affect the pattern of haemoglobin synthesis (Friedenstein et al. 1974 ). However, chromosomal analysis of stromal cells from longterm marrow cultures obtained from recipient lambs at various times after transplantation have shown these to be of predominantly recipient origin , suggesting that at a time when donor haemopoietic cells were producing largely fetal haemoglobin, they were in fact differentiating in an adult microenvironment.
Although a much clearer idea of the cellular mechanisms involved in the regulation of globin gene expression is beginning to emerge, the findings discussed above are of little comfort to those anxious to manipulate the HbF-+HbA switch, as it is likely that an internal program, especially one based on numbers of cell divisions, would be less easy to modify than one based on environmental factors. A quite different therapeutic approach to increasing fetal haemoglobin production during adult life was highlighted by the report by Ley et al. (1982) of temporary clinical improvement in a patient with /1-thalassaemia intermedia given a short course of the drug 5-azacytidine. To understand the rationale behind this unusual approach it will be helpful to consider briefly some molecular rather than cellular aspects of gene expression.
It has been recognized for some time that there are major structural differences in the DNA of genes which are being actively transcribed (such as the globin genes in erythroid cells) and those that are not. At any given moment, the bulk of DNA in a particular cell is transcriptionally inactive by virtue of its being condensed as heterochromatin, whilst the small amount of 'active' DNA has a more open configuration that can be recognized by its susceptibility to digestion in vitro by pancreatic DNAase (Young et al. 1978 , Groudine et al. 1983 . Another way in which active and inactive genes appear to differ is in the degree to which the cytosine residues of DNA are methylated (Busslinger et al. 1983) , and it is possible that methylation is an important factor in gene regulation (Bird 1984) . For example, DNA in the region of the y globin genes is relatively under-methylated in fetal haemopoietic cells, but is methylated during adult life. 5-azacytidine is a cytidine analogue which was originally introduced as a cytotoxic agent for the treatment of leukaemia (Von Hoff et al. 1976 ). It acts principally as a competitive inhibitor of DNA synthesis, but is also incorporated into DNA and inhibits DNA methyltransferase, the enzyme responsible for DNA methylation. When added to certain tissue culture systems, 5-azacytidine induces expression of previously-inactive genes, possibly by an effect on methylation (Busslinger et al. 1983 ). Furthermore, a marked increase in fetal haemoglobin is induced when the drug is administered to anaemic baboons (De Simone et al. 1982) , associated with hypomethylation of DNA in the region of the y genes.
A small number of patients with ,B-thalassaemia (Ley et al. 1982) or sickle-cell disease (Charache et al. 1983 ) have been treated with short courses of 5-azacytidine, and increased production of fetal haemoglobin, and in some an increase in total haemoglobin levels, has been observed, associated in each case with hypomethylation of total DNA and DNA in the y gene region. There are, however, considerable reservations about this approach. 5-azacytidine is a toxic drug, even in comparison with other anti-leukaemic agents, and for this reason is unlikely to have a useful role in the management of genetic disorders. This does not, of course, preclude the possibility that a less toxic drug with actions confined to inhibition of DNA methyltransferase could be developed. A more worrying problem is the lack of evidence that the temporary clinical improvement noted with this drug was due to the intended effect, namely increased expression of y genes, caused directly by drug-induced demethylation of nearby DNA. 5-azacytidine is a cell-cycle-specific cytotoxic agent which one would thus expect to be most toxic to the most actively dividing erythroid progenitor cells in the marrow. This could stimulate earlier progenitors into premature terminal differentiation (Torrealba de Ron et al. 1984), a situation which is associated with increased HbF production by the progeny of these cells and which has been proposed as the mechanism underlying the 'reactivation of fetal haemoglobin synthesis which occurs during periods of erythroid stress (Papayannopoulou et al. 1980) . Studies with other cytotoxic agents which do not affect DNA methylation support this interpretation (Letvin et al. 1984 , Papayannopoulou et al. 1984 . Of course, it may not matter to the patient how fetal haemoglobin production is increased so long as it is sufficient to relieve symptoms; the difficulty will be finding a drug which has cytotoxic actions confined to erythroid progenitors.
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